Medications

Mining data for the history of pharmaceutical development

(Medical Xpress)—Yale's Michael Kinch spent his spare time in the last year creating a massive database that encompasses the entire history of drug development in the United States. In a series of 20 articles scheduled ...

Medications

FDA approves first generic versions of Cymbalta

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

Medications

US group seeks to block Gilead drug patent in India

A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

Medications

US panel wants changes to Avandia safety measures (Update)

US government health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously ...

Medications

US experts review heart attack risk of diabetes drug

GlaxoSmithKline's controversial diabetes drug Avandia, restricted in the US and banned in Europe over concerns it raises heart attack risk, is getting a second look this week by US medical experts.

Medications

FDA weighs lifting safety restrictions on Avandia (Update 2)

A former blockbuster diabetes pill that was subjected to major safety restrictions in 2010 may be less risky than once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug Avandia.

Medications

Lundbeck profit jumps but warns on generic pressure

Danish pharmaceutical company Lundbeck Wednesday posted a higher than expected quarterly net profit, helped by the expansion of an alliance with Japan's Otsuka and the divestment of a US portfolio of non-core products.

Medications

Fearing abuse, US blocks generic OxyContin (Update)

U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.

page 1 from 3